Sprint Bioscience AB (publ)

Stockholm Stock Exchange SPRINT.ST

Sprint Bioscience AB (publ) EBITDA for the year ending December 31, 2023: USD -205.30 K

Sprint Bioscience AB (publ) EBITDA is USD -205.30 K for the year ending December 31, 2023, a 96.42% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Sprint Bioscience AB (publ) EBITDA for the year ending December 31, 2022 was USD -5.73 M, a -112.48% change year over year.
Sprint Bioscience AB (publ) EBITDA for the year ending December 31, 2021 was USD -2.70 M, a 41.53% change year over year.
Sprint Bioscience AB (publ) EBITDA for the year ending December 31, 2020 was USD -4.61 M, a -121.32% change year over year.
Sprint Bioscience AB (publ) EBITDA for the year ending December 31, 2019 was USD -2.08 M, a 40.37% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Stockholm Stock Exchange: SPRINT.ST

Sprint Bioscience AB (publ)

CEO	Mr. Johan Emilsson
IPO Date	Nov. 7, 2014
Location	Sweden
Headquarters	Novum
Employees	36
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Sprint Bioscience AB (publ) develops pharmaceutical products in the areas of cancer and metabolism in Sweden, Europe, the United States, and Asia. It engages in developing VPS34, a drug candidate for the treatment of various types of cancer; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism and type 2 diabetes. Sprint Bioscience AB (publ) was founded in 2009 and is based in Huddinge, Sweden.

Key trends

Past 5 years